GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integrum AB (OSTO:INTEG B) » Definitions » EV-to-FCF

Integrum AB (OSTO:INTEG B) EV-to-FCF : -48.25 (As of Jun. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Integrum AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Integrum AB's Enterprise Value is kr966.28 Mil. Integrum AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 was kr-20.03 Mil. Therefore, Integrum AB's EV-to-FCF for today is -48.25.

The historical rank and industry rank for Integrum AB's EV-to-FCF or its related term are showing as below:

OSTO:INTEG B' s EV-to-FCF Range Over the Past 10 Years
Min: -272.86   Med: -11.02   Max: -2.84
Current: -45.68

During the past 9 years, the highest EV-to-FCF of Integrum AB was -2.84. The lowest was -272.86. And the median was -11.02.

OSTO:INTEG B's EV-to-FCF is ranked worse than
100% of 360 companies
in the Medical Devices & Instruments industry
Industry Median: 27.515 vs OSTO:INTEG B: -45.68

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Integrum AB's stock price is kr53.00. Integrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was kr-0.240. Therefore, Integrum AB's PE Ratio for today is At Loss.


Integrum AB EV-to-FCF Historical Data

The historical data trend for Integrum AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrum AB EV-to-FCF Chart

Integrum AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -4.07 -5.08 -128.16 -13.78 -12.27

Integrum AB Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.13 -12.27 -11.05 -22.89 -39.97

Competitive Comparison of Integrum AB's EV-to-FCF

For the Medical Devices subindustry, Integrum AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrum AB's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Integrum AB's EV-to-FCF falls into.



Integrum AB EV-to-FCF Calculation

Integrum AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=966.276/-20.025
=-48.25

Integrum AB's current Enterprise Value is kr966.28 Mil.
Integrum AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-20.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integrum AB  (OSTO:INTEG B) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Integrum AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=53.00/-0.240
=At Loss

Integrum AB's share price for today is kr53.00.
Integrum AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Integrum AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Integrum AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrum AB (OSTO:INTEG B) Business Description

Traded in Other Exchanges
Address
Krokslatts Fabriker 50, Molndal, SWE, SE-431 37
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.

Integrum AB (OSTO:INTEG B) Headlines

No Headlines